Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aim Immunotech Inc (NY: AIM )

0.2301 +0.0021 (+0.92%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aim Immunotech Inc

< Previous 1 2 3 4 5 Next >
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
Via Benzinga
AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer
AIM ImmunoTech Inc (NYSE: AIM) announced the publication of positive data from a single-center named patient program treating advanced and metastatic pancreatic... 
Via Benzinga
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /... 
From JTC Team, LLC
Via AccessWire
Earnings Scheduled For November 11, 2021
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape... 
Via Benzinga
AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses
AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease
AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two... 
Via Benzinga
Exposures COVID-19 Product Safety
AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients
AIM ImmunoTech Inc (NYSE: AIM) has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for Post-COVID-19 Cognitive... 
Via Benzinga
Exposures Product Safety
AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction
AIM ImmunoTech Inc (NYSE: AIM) has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of Ampligen as a potential... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For August 13, 2021
Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million. • Fangdd... 
Via Benzinga
Earnings Scheduled For May 14, 2021
Companies Reporting Before The Bell • Sogou (NYSE:SOGO) is projected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is estimated to report... 
Via Benzinga
AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study
AIM ImmunoTech Inc (NYSE: AIM) has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.